

Amoxicillin + clavulanic acid

Essential medicine status 

Section: [6. Anti-infective medicines](#) > [6.2. Antibacterials](#) > [6.2.1. Access group antibiotics](#)

EMLc

ATC codes: [J01CR02](#)

Indication	Acute sinusitis ICD11 code: CA01
INN	Amoxicillin + clavulanic acid
Medicine type	Chemical agent
Antibiotic groups	A ACCESS
List type	Core (EML) (EMLc)
Formulations	Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection ; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid (EMLc) ; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid (EMLc) Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt) (EMLc) ; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) (EMLc) Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt) ; 875 mg (as trihydrate) + 125 mg (as potassium salt) (EML)
EML status history	First added in 2017 (TRS 1006) Changed in 2023 (TRS 1049)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents . 
Wikipedia	Amoxicillin + clavulanic acid 
DrugBank	Amoxicillin  , Clavulanic acid (Clavulanate) 

Expert Committee recommendation

The Expert Committee recommended the inclusion of a new strength, child-friendly dispersible tablet formulation of amoxicillin + clavulanic acid (200 mg + 28.5 mg) as an Access group antibiotic on the core list of the EMLc for treatment of bacterial infections in children – specifically those infections for which amoxicillin + clavulanic acid is already recommended on the EMLc. The Committee noted that the 7:1 ratio of amoxicillin to clavulanic acid is associated with similar efficacy to the 4:1 ratio but has a reduced frequency of gastrointestinal adverse effects. The Committee endorsed the importance of age-appropriate formulations to better meet the dosing needs of children. Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of new formulations of amoxicillin (dispersible, scored tablet, 250 mg and 500 mg) to the EMLc. - the addition of a new formulation of amoxicillin + clavulanic acid (dispersible tablet 250 mg + 62.5 mg) to the EMLc.

EML recommendations: Acute sinusitis

First choice

Second choice

amoxicillin

amoxicillin + clavulanic acid

